Lilly to buy three vaccine developers in deal worth $3.8bn

Eli Lilly and Company (LLY) said on Tuesday it would buy Curevo Inc., LimmaTech Biologics AG and The Vaccine Company in deals worth up to $3.8 billion, taking its acquisition push deeper into infectious disease. In a statement announcing the acquisitions, Lilly said the package would broaden its vaccine portfolio rather than rely only on internal research.

The three deals include up to $1.5 billion for Curevo, up to $780 million for LimmaTech and up to $1.55 billion for The Vaccine Company, according to Reuters’ account of the transactions. Together, they give Lilly three external pipeline bets without tying the group to one takeover large enough to dominate the balance sheet or one integration story.

For dealmakers, the structure may matter almost as much as the assets themselves. Lilly is spreading scientific and execution risk across several programmes linked to one theme instead of making a single large wager on a late-stage platform. That is usually easier to defend to investors than an acquisition whose outcome rests on one programme.

Bundling the transactions into one announcement also changed the message. Three separate tuck-ins became a portfolio call on vaccines and infectious disease. Lilly signaled that it wants more than one route into the area, rather than treating it as a side project.

In the company announcement, Daniel M. Skovronsky, Lilly’s chief scientific and medical officer, said: “These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences.”

His comment framed the deals around prevention, but it also pointed to capital deployment. Lilly presented the purchases as a coordinated build-out, not three isolated swings, giving the company room to add assets across several programmes rather than hinge the strategy on a single make-or-break purchase.

Why the structure matters

Trade outlet Fierce Biotech’s read of the package described the move as the latest step in Lilly’s acquisition run. For investors, the more immediate question is how much risk Lilly is taking on at once. Three smaller transactions can widen the company’s infectious-disease footprint, leave space for further business development and keep the integration work compartmentalised.

The “up to” wording attached to each price tag carries its own message. In biotech M&A, headline values often include milestones and other contingent payments rather than cash due at closing. Even without the full mechanics in public view, the phrasing suggests Lilly is buying optionality rather than writing one large cheque on day one.

Reuters also quoted analyst Shams Afzal on why the package may be easier for the market to absorb. “The bite-sized price tag in the overall scheme of things certainly helps,” Afzal said.

At up to $3.8 billion combined, the transactions are large enough to show intent but still small enough that investors may spend more time on strategic fit than on balance-sheet strain. Tuesday’s move read less like a megadeal than a targeted expansion across one corner of biotech.